Trastuzumab may inhibit the growth and proliferation of cancer cells through several possible mechanisms, including activating the immune system against cancer cells through an effect known as antibody-dependent cell-mediated cytotoxicity, inhibiting the MAPK and PI3K/Akt pathways, and enlisting ubiquitin to internalize and degrade HER2. Here, AKT1 is linked to cancer.